MeVis Medical Solutions AG (FRA:M3V) ROCE %: 0.18% (As of Mar. 2026)


FRA:M3V MeVis Medical Solutions AG FRA:M3V
66 GF Score
Price €23.20
GF Value €22.52
! 4 Warning Signs
View Full Analysis

What is MeVis Medical Solutions AG ROCE %?

MeVis Medical Solutions AG FRA:M3V 66 ROCE % is 0.18% as of Mar. 2026. GuruFocus rates FRA:M3V with a GF Score™ of 66/100 and a GF Value™ of €22.52. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MeVis Medical Solutions AG's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.18%.

MeVis Medical Solutions AG  (FRA:M3V) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MeVis Medical Solutions AG ROCE % Related Terms

MeVis Medical Solutions AG ROCE % Historical Data

* Premium members only.

The historical data trend for MeVis Medical Solutions AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeVis Medical Solutions AG ROCE % Chart

MeVis Medical Solutions AG Annual Data
Trend Dec15 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.56 37.20 23.76 22.78 16.28

MeVis Medical Solutions AG Semi-Annual Data
Jun16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.08 23.66 17.04 16.01 0.18
FRA:M3V
66GF Score
MeVis Medical Solutions AG FRA:M3V
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeVis Medical Solutions AG ROCE % Calculation

MeVis Medical Solutions AG's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=3.279/( ( (26.484 - 6.357) + (25.886 - 5.72) )/ 2 )
=3.279/( (20.127+20.166)/ 2 )
=3.279/20.1465
=16.28 %

MeVis Medical Solutions AG's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=0.036/( ( (25.886 - 5.72) + (23.162 - 2.924) )/ 2 )
=0.036/( ( 20.166 + 20.238 )/ 2 )
=0.036/20.202
=0.18 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.18% mean?
MeVis Medical Solutions AG (FRA:M3V) has a ROCE % of 0.18% as of Mar. 2026.
Is MeVis Medical Solutions AG's ROCE % too high?
MeVis Medical Solutions AG's current ROCE % is 0.18%. The Healthcare Providers & Services industry median ROCE % is 6.41. MeVis Medical Solutions AG's value of 0.18% is 97.2% below this industry median. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's ROCE % compare to VEEV and BTSG?
MeVis Medical Solutions AG's ROCE % of 0.18% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. MeVis Medical Solutions AG's value of 0.18% is 97.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeVis Medical Solutions AG's current ROCE % of 0.18% is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeVis Medical Solutions AG's current ROCE % is 0.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
MeVis Medical Solutions AG (FRA:M3V) has a current ROCE % of 0.18%. The stock's GF Value™ is €22.52, compared to a current price of €23.20 — trading 3% above its estimated fair value. The current ROCE % is 0.18% and 97.2% below the Healthcare Providers & Services industry median of 6.41. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current ROCE % is 0.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?

Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued. The current stock price of €23.20 is trading 3% above its estimated GF Value™ of €22.52.

Key valuation signals for FRA:M3V:

  • ROCE %: 0.18%
  • GF Value™: €22.52 vs. price of €23.20 (3% above fair value)
  • GF Score™: 66/100 with 4 warning signs
  • Industry Position: 97.2% below the Healthcare Providers & Services median

No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MeVis Medical Solutions AG Business Description

Other Exchanges 0HI7:UKM3V:Germany
Address Caroline-Herschel-Strasse 1, Bremen, DEU, 28359
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
66GF Score

Get the complete analysis for FRA:M3V

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.20
Price
€22.52
GF Value